Shimadzu has joined forces with the France-based AlsaChim company, an independent contract research and development organization. AlsaChim specializes in stable isotope-labelled compounds, metabolites and pharmaceutical related substances, and analytical purposes. With immediate effect, Shimadzu Europe has acquired AlsaChim by 100%.The brand name will be kept for the future complemented by the subtitle “a Shimadzu Group Company”. The price for the acquisition is kept confidential.
Through the acquisition of AlsaChim, Shimadzu also adds value to its European Innovation Center (EUIC), particularly for the clinical segments which is one of EUIC’s focus areas. This innovations-oriented Think Tank combines academic-scientific expertise from well-known European universities with Shimadzu’s cutting-edge technology to provide even more customer-focused service.
“With AlsaChim, we have a strong partner in our organization who is able to finalize and validate new application kits and utilize the developments done by EUIC and transfer them into ready-to-use products”, said Bjoern-Thoralf Erxleben, Senior Manager Analytic Shimadzu Europa, based in Duisburg, Germany.
Shimadzu and AlsaChim expect new customers for both brands. The EUIC and its strong cooperation partners provide a platform for new and additional business. Having with AlsaChim a strong partner for development of application kit solutions, this will increase Shimadzu’s business in the clinical and diagnostic market, but also in other market segments. “Being part of the Shimadzu Group, the AlsaChim brand expects additional demand for their products in new sales areas as well as stronger marketing support than before”, said Jean-Francois Hoeffler, President of AlsaChim.